The Global Fetal Bovine Serum Market is driven by
Increasing R&D activities in pharmaceutical and biotechnology industries

Fetal bovine serum (FBS) is commonly used in cell culture
growth media and is derived from blood drawn from fetal calves which is a
by-product of the beef industry. It is heat-inactivated to neutralize any
complement proteins present from the serum. FBS contains growth-promoting
proteins like insulin, transferrin and other components which support the
growth of mammalian cells in cultures. It is an essential reagent for in vitro
cell culture and is used extensively in research, bioproduction and
manufacturing applications.



The fetal bovine serum market is estimated to be valued at USD 1.86 Bn
in 2024 and is expected to reach USD 4.54 Bn by 2031,
exhibiting a compound annual growth rate (CAGR) of 13.6% from 2024 to
2031.

The increasing R&D investments in pharmaceutical and
biotechnology industries is primarily driving the Fetal
Bovine Serum Market Demand. FBS finds widespread application in
research related to drug discovery, life sciences and development of new
diagnostics and vaccines.



Key Takeaways



Key players operating in the fetal bovine serum market are Merck KGaA, Thermo
Fisher Scientific Inc., HiMedia Laboratories, Bio-Techne, PAN-Biotech, Atlas
Biologicals, Inc., Rocky Mountain Biologicals, Cytiva, Sartorius AG, and
SeraCare Life Sciences. These players are focusing on innovation, partnerships
and robust supply chains to cater to the growing demand.

Get More
Insights on- Fetal
Bovine Serum Market